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Objectives
We wanted to investigate regional variations in the organisms reported to be causing peri-
prosthetic infections and to report on prophylaxis regimens currently in use across England.
Methods
Analysis of data routinely collected by Public Health England’s (PHE) national surgical site 
infection database on elective primary hip and knee arthroplasty procedures between April 
2010 and March 2013 to investigate regional variations in causative organisms. A separate 
national survey of 145 hospital Trusts (groups of hospitals under local management) in 
England routinely performing primary hip and/or knee arthroplasty was carried out by 
standard email questionnaire.
Results
Analysis of 189 858 elective primary hip and knee arthroplasty procedures and 1116 surgical 
site infections found statistically significant variations for some causative organism between 
regions. There was a 100% response rate to the prophylaxis questionnaire that showed 
substantial variation between individual trust guidelines. A number of regimens currently in 
use are inconsistent with the best available evidence.
Conclusions
The approach towards antibiotic prophylaxis in elective arthroplasty nationwide reveals 
substantial variation without clear justification. Only seven causative organisms are 
responsible for 89% of infections affecting primary hip and knee arthroplasty, which cannot 
justify such widespread variation between prophylactic antibiotic policies.
Cite this article: Bone Joint Res 2015;4:181–189.
Article focus
- Prophylactic antibiotics are often adminis-
tered in the peri-operative period to reduce
the risk of infection following joint arthro-
plasty surgery.
Key messages
- There is widespread variation in use of pro-
phylactic antibiotics for elective lower limb
arthroplasty. This variation is not justified by
any regional variation in the organisms
believed to have caused peri-prosthetic joint
infections.
Strengths and limitations
- Strengths - data on organisms thought to
have caused surgical site infections were
extracted from a national surveillance data-
base. A survey of antibiotic prophylaxis regi-
mens achieved responses from every NHS
organisation performing elective hip and
knee arthroplasty.
- Limitations - this cross-sectional study has
identified an important public health prob-
lem (unjustified variation in practice) but
cannot prove a link between intervention
(antibiotic choice) and population-level
outcomes (organism distribution).
Introduction
Total hip arthroplasty (THA) and total knee
arthroplasty (TKA) are two of the most
commonly performed orthopaedic proce-
dures. Annually, over 86 488 THAs and over
Freely available online
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90 842 TKAs are performed in the United Kingdom,
and over 231 000 THAs and 542 000 TKAs in the United
States.1,2 Although they are safe and effective opera-
tions, prostheses can fail due to aseptic loosening, dis-
location, fracture, or infection.3 Surgical site infection
(SSI), which includes prosthetic joint infection (PJI), has
a prevalence of 0.7% to 2.1% in primary THAs and
0.6% to 1.8% in primary TKAs.4-6 With high-quality
post-discharge surveillance, median infection rates
were estimated to be 1.6% and 2.4% for THA and TKA,
respectively, from 2011 to 2012 in England.7 PJI is the
reason for 14.8% of THA revisions and the most com-
mon indication (25.2%) for revising TKAs.8 Each PJI is
estimated to cost $30 000 to $40 000 (£18 374 to
£24 500) and this complication will account for 50% of
all hospital resources used for revision TKA by 2016.9 It
is therefore necessary to optimise the use of safe, effec-
tive, and low-cost interventions to reduce the burden
of PJI after lower limb joint arthroplasty.10
Over half of PJIs are caused by Staphylococcus species,
particularly Staphylococcus (S.) aureus and coagulase-
negative staphylococci (CoNS).4 Met(h)icillin-resistant
S. aureus (MRSA) is isolated from 8% of infected prosthe-
ses, and anaerobes are isolated from 7% of infected pros-
theses. However, retrospective case series have shown
that up to 36% of prostheses infections are polymicro-
bial.11 As most organisms are commensal skin flora, they
are presumed to have inoculated the prosthesis at joint
implantation.10 Less commonly, organisms can spread
haematogenously from distant sites, for example from
the urinary tract.
Interventions to reduce rates of PJI include MRSA decol-
onisation and met(h)icillin-sensitive S. aureus (MSSA)
decolonisation, pre-operative nutritional optimisation,
good diabetic control, careful hair removal, instrument
sterilisation and skin decontamination, laminar flow the-
atres, body exhaust suits, and antibiotic-impregnated
cement. Another key intervention is the use of peri-
operative prophylactic antibiotics.12-14
In a pooled analysis of seven studies, the administration
of prophylactic antibiotics reduced the relative risk (RR) of
wound infection by 81% (RR 0.19; 95% confidence inter-
val (CI) 0.12 to 0.31). This translates to an absolute risk
reduction of 8%, meaning that one wound infection
would be prevented for every 13 people treated com-
pared with no administration of antibiotics.15 It is, how-
ever, difficult to recommend a particular regimen based
on current studies, which vary in drug selection, dose,
timing, and use of post-operative antibiotics. Antibiotic
regimens might carry different risks and side-effect
profiles, e.g., hypersensitivity reactions (including ana-
phylaxis), acute kidney injury, and Clostridium difficile
infection (CDI).16-19
The aims of this paper are to report the bacterial spec-
trum of infections across England, to document national
variation in antibiotic prophylaxis for primary THA and
TKA, to identify emerging trends in the use of specific
regimens, and to recommend an optimal regimen based
on current evidence.
Materials and Methods 
Current pathogens in hip and knee arthroplasty infec-
tions in England. We analysed 189 858 elective primary
hip and knee arthroplasty procedures and 1116 inpatient
or re-admission SSIs submitted by 184 NHS hospitals
(representing 142 NHS Trusts and ten independent NHS
treatment centres) to the Public Health England (PHE)
national SSI database between April 2010 and March
2013. As the survey on surgical antibiotic prophylaxis was
carried out in 2013, the PHE organism data available at the
time were for April 2012 to April 2013. The dataset was
therefore expanded to include data from the previous
two years in order to increase the sample size. Although
mandatory orthopaedic data were collected from April
2004, the inclusion of historical data that predated vari-
ous national policies on healthcare-associated infections
would have introduced bias and over-estimation of the
burden of S. aureus. Participating hospitals follow a stan-
dard protocol of internationally-recognised case defini-
tions for superficial, deep, and organ-space SSIs.
Hospitals also undertake systematic prospective follow-
up for the capture of cases.20-22 The standard follow-up
period is 30 days for superficial SSIs and up to one year
(365 days) for deep and/or organ-space SSIs.
Since April 2004, all NHS Trusts in England have been
required to undertake mandatory surveillance in ortho-
paedic surgery. The four orthopaedic categories are hip
arthroplasty, knee arthroplasty, repair of the neck of the
femur, and reduction of long-bone fracture. PHE manages
the SSI surveillance programme and publishes the rates of
SSI by an NHS Trust on an annual basis for the orthopaedic
modules. Since public reporting of orthopaedic SSI is at
Trust level, the minimum requirement is participation by
one hospital site for at least one surveillance quarter in one
of the four mandatory orthopaedic categories.
Data are submitted via the PHE secure web-based portal.
All data are checked for errors using an inbuilt automated
validation system. For example inconsistencies in date val-
ues are identified and flagged to the user. SSIs with insuffi-
cient SSI criteria entered or superficial SSIs detected
beyond 30 days are disallowed to avoid over-reporting of
SSIs that do not meet the standard case definitions. Report-
ing on causative micro-organisms is optional, but must be
based on clinically-significant isolates. 
The SSIs included in this analysis were those detected
during the inpatient stay, or on re-admission following
initial hospital discharge, as these methods of detection
are a requirement for all participating hospitals. Other
forms of post-discharge surveillance (patient wound
healing questionnaires or follow-up through review or
outpatient clinics) are optional and used inconsistently,
and thus were excluded from this study. 
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We analysed superficial, deep, and organ-space SSI iso-
lates together then conducted a separate subgroup anal-
ysis restricted to deep and organ-space SSI isolates. All
English NHS Trusts participated in this mandatory ortho-
paedic surveillance in 2010/2011, three failed to do so in
2011/2012, and two in 2012/2013.22
The proportion of participating hospitals undertaking
continuous surveillance (all four quarters) increased year
on year, from 51% in 2010/2011 to 56% in 2012/2013 for
hip prosthesis and from 52% to 55% for knee prosthesis
over the same time period.22
The four PHE ‘super regions’ used were London, Mid-
lands and the East of England, the North of England, and
the South of England.
Data on primary indications involving trauma/fracture
or revision surgery (including revisions for aseptic loosen-
ing) were excluded from this analysis. Other indications
for surgery were included (avascular necrosis, inflamma-
tory joint disease, osteoarthritis, revision, and other).
Current regimens for prophylaxis in England. As a separate
initiative from PHE’s routine surveillance activities, all 144
acute hospital Trusts performing primary hip and knee
arthroplasty in England were contacted. Responses were
received from 100% of these Trusts. Information gover-
nance leads at each Trust were emailed a standard ques-
tionnaire in October 2013 and those that did not respond
within 30 days were contacted by telephone. Telephone
calls were to the duty microbiologist, antibiotic pharma-
cist, medicines information line, or orthopaedic junior
doctor on call. In all cases, sources were asked for infor-
mation from their hospital’s antibiotic policy. Where the
individual contacted was not aware of the local policy,
another individual from the list of suitable contacts was
contacted.
Contacts were asked ‘Which antibiotics are given pro-
phylactically to patients undergoing elective primary THA
or TKA at induction and/or post-operatively? What modi-
fications are made for patients with a serious allergy to
penicillin or a history of MRSA infection/colonisation?
What doses are administered? What are the dosing inter-
vals? Are there any special circumstances specified in their
guidelines, e.g. repeated doses for prolonged surgery or
excessive loss of blood?’.
Non-normally distributed continuous data were
described using medians with interquartile ranges.
Fisher’s exact test was used to compare differences in
categorical outcomes between groups as there were
small numbers in some cells. Statistical analyses were per-
formed using Stata 13.0 (StataCorp, College Station,
Texas) and p < 0.05 (two-tailed) was adopted as the
threshold for significance.
Results
Patient characteristics of primary elective hip or knee
procedures. The distribution of the patients’ age, gender
and ASA score distribution were broadly similar across the
two modules. Patients aged 65 to 74 years accounted for
the largest proportion of procedures. Within this group,
there were more patients receiving a knee prosthesis,
compared with those receiving a hip prosthesis (38.1%
and 34.4%, respectively). Patients aged < 45 years
accounted for the smallest proportion across both popu-
lations, however, it was slightly higher in the THA group
(4% and 1%, respectively). Female patients accounted for
a slightly higher proportion in the THA than the TKA
group (60.2% and 58.0%, respectively). Patients with
ASA score of 3 or more were similar across the hip and
knee modules (19.4% and 20.3%, respectively).
The median time from procedure date to onset of SSI
was based on monomicrobial SSIs. Overall the median
time to onset of SSI was 18 days (interquartile range (IQR)
11 to 29, minimum and maximum 1 to 363). The median
time to onset of S. aureus SSIs was 19 days (IQR 12 to 29, 1
to 362); 16 days for CoNS SSIs (IQR 11 to 27, 1 to 345) and
17 days for Enterobacteriaceae SSIs (IQR 11 to 25, 2 to 267). 
Pathogens reported to cause hip and knee arthroplasty
infections in England. There were 1116 inpatient/re-
admission SSIs, of which 73.3% (n = 818) included data on
causative micro-organisms (Table I). 73.8% (n = 604) of
these SSIs had a monomicrobial aetiology (n = 604) and
26.2% (n = 214) were polymicrobial. SSIs with organism
data yielded a total of 1083 isolates and, of these isolates,
69.1% (n = 748) related to deep and/or organ-space SSIs. 
MSSA was the predominant pathogen across England,
accounting for 27.0% of isolates (n = 291) followed by
coagulase-negative staphylococci (CoNS) at 25.5%
(n = 276). MRSA accounted for 4.2% (n = 45) of total
isolates. The seven most common causative organisms
accounted for 89% of all SSI isolates following THAs and
TKAs across the four PHE super regions.
At regional level, staphylococci (MSSA, MRSA, and
CoNS) accounted for 57% of isolates with a similar distri-
bution across the PHE super regions. The burden of MRSA
was, however, significantly higher in the Midlands and
East of England compared with the other three regions
(7.4% vs 2.8%; Fisher’s exact test; p = 0.001).
The burden of Pseudomonas spp. was significantly
higher in London compared with the three regions com-
bined (8.9% vs 3.2%; Fisher’s exact test: p = 0.005). 
Sub-group analysis limited to deep and organ space
SSIs (n = 748) found that CoNS were the predominant
pathogens and accounted for 27% of isolates (n = 209)
followed by MSSA at 25% (n = 184). MRSA accounted for
3.3% of these isolates. Overall, staphylococci accounted
for 56% of isolates in this analysis. Stratified analyses by
PHE super region showed that the burden of MRSA was
also significantly higher in the Midlands and East of Eng-
land region compared with the other three regions com-
bined (6.3% vs 2.2%; Fisher’s exact test: p = 0.010). The
burden of Pseudomonas spp. was also significantly higher
in London compared with other three regions combined
(8.2% vs 2.8%; Fisher’s exact test: p = 0.028).
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The reasons for the regional differences in MRSA and
Pseudomonas spp. are not entirely clear. However, labora-
tory data reported to PHE’s voluntary surveillance system
(LabBase2) from 2010 to 2013 shows that the rate of infec-
tions in the bloodstream due to Pseudomonas spp. was
consistently higher in London compared with the other
three regions over his period even with the declining
trend.23 The corresponding analysis for MRSA was not
available although a separate report showing trends by
smaller geographical units called Area Teams (ATs) showed
that ATs within the Midlands and East England region did
not show the highest rates of bloodstream infections due
to MRSA than other ATs.24 The MRSA result from the SSI
programme is perplexing and needs further study. 
Current prophylaxis regimens in England
Routine prophylaxis. The three most common antibiot-
ics or antibiotic combinations made up 126/146 (87%) of
observed practice. Flucloxacillin in combination with
gentamicin was the most common regimen, with 57/146
(39%) of Trusts using it as their preferred regimen. Cefu-
roxime was used as the preferred regimen by 44/146
(30%), with teicoplanin plus gentamicin being the third
most popular 25/146 (17%). There were ten further pre-
ferred regimens used by the remaining 20 Trusts.
Figure 1 illustrates the range of routine prophylactic
antibiotic regimens used throughout England. Two Trusts
employed two different regimens in this category of
patient based on age. Therefore the denominator is 146.
Prophylaxis in patients with penicillin allergy. The two
most common antibiotic/antibiotic combinations made
up 128/145(88%) of observed practice. Teicoplanin in
combination with gentamicin was the most common
regimen, with 90/145 (62%) of Trusts using it as their pre-
ferred regimen. Teicoplanin alone was used as the pre-
ferred regimen by 36/145 (26%). There were 12 further
preferred regimens used by the remaining 20 Trusts.
Figure 2 illustrates the spread of prophylactic antibiotic
regimens employed throughout England for patients
who are allergic to penicillin. One Trust employed two
different regimens in this category. Therefore the
denominator is 145.
Prophylaxis in patient with a high risk of developing
MRSA SSI infection. The two most common antibiotic/
antibiotic combinations made up 123/146 (84%) of
observed practice. Teicoplanin, in combination with
gentamicin, was the most common, with 87/146 (60%) of
Trusts using it as their preferred regimen. Teicoplanin
alone was used as the preferred regimen by 34/146
(24%). There were 11 further preferred regimens used by
the remaining 20 Trusts.
Figure 3 illustrates the distribution of prophylactic
antibiotic regimens employed throughout England for
patients at high risk of developing MRSA SSI infection.
Two Trusts employed two different regimens in this cat-
egory, therefore the denominator is 146.
Discussion
Our study has shown that 89% of SSIs in hip and knee
arthroplasty in England are reportedly caused by the
same seven organisms. However, we also found higher
rates of MRSA PJI in the Midlands and East of England and
Table I. Micro-organisms reported as causing surgical site infection (SSI) following hip or knee prosthesis surgery (Apr 2010 to Mar 2013)
London
Midland and 
East of England
North of 
England
South of
England
England 
(total)
No. % n % n % n % n % n %
All SSI isolates MSSA 25 20.2 88 27.2 87 26.9 91 29.2 291 26.9
MRSA 3 2.4 24 7.4 8 2.5 10 3.2 45 4.2
CoNS 39 31.5 73 22.5 85 26.3 79 25.3 276 25.5
Enterobacteriaceae 20 16.1 52 16.0 58 18.0 39 12.5 169 15.6
Other bacteria* 10 8.1 35 10.8 26 8.0 40 12.8 111 10.2
Enterococcus spp. 11 8.9 20 6.2 31 9.6 17 5.4 79 7.3
Streptococcus spp. 5 4.0 24 7.4 17 5.3 21 6.7 67 6.2
Pseudomonas spp. 11 8.9 6 1.9 11 3.4 14 4.5 42 3.9
Fungi 0 0.0 2 0.6 0 0.0 1 0.3 3 0.3
Total 124 100 324 100 323 100 312 100 1,083 100
Deep or organ-space
SSI isolates
CoNS* 23 31.5 51 24.6 71 30.5 64 27.2 209 27.9
MSSA 18 24.7 50 24.2 62 26.6 54 23.0 184 24.6
MRSA 1 1.4 13 6.3 3 1.3 8 3.4 25 3.3
Enterobacteriaceae 12 16.4 34 16.4 40 17.2 35 14.9 121 16.2
Other bacteria† 5 6.8 20 9.7 19 8.2 32 13.6 76 10.2
Enterococcus spp. 5 6.8 18 8.7 18 7.7 13 5.5 54 7.2
Streptococcus spp. 3 4.1 18 8.7 12 5.2 19 8.1 52 7.0
Pseudomonas spp. 6 8.2 2 1.0 8 3.4 9 3.8 25 3.3
Fungi 0 0.0 1 0.5 0 0.0 1 0.4 2 0.3
Total 73 100 207 100 233 100 235 100 748 100
* The majority in this group comprised diptheroids/Corynebacterium spp. (40%) followed by unidentified organisms (31%) 
† The majority in this group comprised diptheroids/Corynebacterium spp. (42%) followed by unidentiﬁed organisms (28%)
MSSA, met(h)icillin-sensitive S. aureus; MRSA, met(h)icillin-resistant S. aureus; CoNs,coagulase-negative staphylococci
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higher rates of Pseudomonas spp. PJI in London. Without
further data, it is difficult to understand exactly why these
trends exist. Centres reporting higher burdens of MRSA or
pseudomonas may be tertiary referral centres for complex
arthroplasties from elsewhere. These centres may therefore
encounter larger volumes of patients with previous
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Fig. 1
Graph showing the prophylactic antibiotic regimens in general use for patients undergoing hip and knee arthroplasty.
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hospital admissions and antibiotic exposure that could
render them more prone to infection with these
organisms.
The low prevalence of SSI-related MRSA is against a
background of falling numbers of SSIs caused by this
organism, possibly related to national policies directed at
reducing the MRSA.25 It is worth noting, however, that
Trusts may choose to adopt these recommendations on
an individual basis. 
Although there is a large body of evidence for the use of
prophylactic antibiotics in primary hip and knee arthro-
plasty, there is no clear benefit to using one particular
agent/regimen.26,27 This is unsurprising, given that PJI is a
rare event and that a randomised study would need over
3000 patients per group in order to demonstrate a reduc-
tion in the rate of infection from 2% to 1%, with a power
of 90% at the 95% confidence interval.28 There are no
randomised controlled trials available to guide the choice
of any particular antibiotic regimen. 
Current evidence. The evidence for different antibiotic
regimens as prophylaxis for wound infections following joint
arthroplasty surgery was last reviewed in 2005. This system-
atic review did not find any statistically significant difference
in rates of infection when comparing cephalosporins with tei-
coplanin, cephalosporins with penicillin derivatives, or first-
generation with second-generation cephalosporins. How-
ever, this review was based on poor-quality studies with vari-
able follow-up and unsatisfactory definitions of infection.15
Dose and duration of therapy: cefuroxime. There is strong
evidence for the use of 1.5 g cefuroxime at induction, how-
ever, two randomised controlled trials examining the effec-
tiveness of post-operative doses of cefuroxime found no
statistically significant difference in the prevention of
SSIs.29,30
Dose and duration of therapy: flucloxacillin. Use of a sin-
gle prophylactic dose of flucloxacillin (1g) is supported by
one RCT in which it compared favourably with cefazolin in
clean, semi-elective orthopaedic surgery involving the
implantation of metal work.31
Dose and duration of therapy: gentamicin. There is no
evidence for the use of systemic gentamicin as prophy-
laxis in primary elective THA and TKA surgery. 
Dose and duration of therapy: teicoplanin. Four randomised
controlled trials provide strong evidence for the use of a
single dose of 400 mg of teicoplanin at induction.32-35
Although there is no evidence to suggest that higher
doses or prolonged courses of treatment result in fewer
SSIs, studies have shown that this dose may be inade-
quate for patients weighing over 70 kg.36
Complication profiles: cefuroxime. Although there is
strong evidence for an association between cefuroxime
and CDI in elderly inpatient populations and trauma
patients receiving implantation of metal work, studies
have not shown any association in the elective orthopae-
dic setting.18,37-39 Despite this, our analysis of PHE data
showed that 25.5% of SSI isolates were reportedly due to
87
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Graph showing prophylactic antibiotic regimens in use for patients at a high risk of MRSA colonisation.
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CoNS and 4.2% to MRSA. Cefuroxime is ineffective
against MRSA, and may not be effective against CoNS.
Additional arguments against the continued use of cefu-
roxime include its lack of activity against enterococci and
Pseudomonas spp, and the increasing number of infec-
tions caused by extended spectrum beta-lactamase-
producing organisms.
Complication profiles: flucloxacillin with gentamicin. There
has been an increase in the percentage of Trusts using flu-
cloxacillin in combination with gentamicin – from 1.3%
in 2005 to 38.4% in 2013.40 The efficacy of gentamicin
depends on local strains and sensitivities, but it is usually
active against Enterobacteriaceae, Pseudomonas spp. and
MRSA in the United Kingdom, although rates of resistance
are increasing.
One large, good quality study showed that a single
dose of gentamicin caused a significant increase in the
number of patients suffering from transient acute kidney
injury (AKI).18 Another non-randomised study found an
association between combined high-dose flucloxacillin
with single-dose gentamicin and renal impairment;
including three patients that subsequently required
short-term haemodialysis.41 This was supported by a pro-
spective study in 2013, which showed a highly significant
increase in patients suffering AKI – from 1.7% with cefu-
roxime to 9.5% with combined flucloxacillin and genta-
micin.41
Complication profiles: teicoplanin with gentamicin. Use
of teicoplanin alone is not associated with significant
complications, although it may cause AKI when com-
bined with gentamicin. Advantages of teicoplainin over
vancomycin include a reduced risk of nephrotoxicity and
a quicker speed of pre-operative intravenous administra-
tion, despite increased time for reconstitution. It is admin-
istered as a five-minute intravenous bolus, rather than a
one-hour infusion. Teicoplanin is highly active against
both MRSA and MSSA, although resistance is increas-
ing.28 This regime is also useful in those who are allergic
to penicillin.
The limitations of this study include the absence of data
on the use of antibiotic impregnated cement, and that
microbial profiles provided by super regions may not
directly correspond with causative organism distribution at
Trust level, due to variation between Trusts in each region.
Reporting on micro-organism is optional, and may have
been a potential source of bias. However, the microbial
aetiology among deep-seated SSIs was similar to the over-
all analysis, and so the possibility of bias in the type of
organism being reported does not seem convincing. In
addition, there is no guarantee that the antibiotics admin-
istered as prophylaxis always comply with Trust protocols.
The use of an ecological analysis to examine the
correlation between interventions and outcomes at
population level (prophylaxis choice and organism distri-
bution) does not establish cause and effect. However, it
has been useful in defining a problem in public health
(variation in practice) for future investigation.
In conclusion, this survey outlines current practice with
regard to antibiotic prophylaxis for elective primary TKA
and THA in England. It reveals a disparity in the choice of
antibiotic(s), duration of therapy and interpretation of the
available evidence in the literature without clear justifica-
tion. A number of regimens currently in use do not
appear to take account of the most recent evidence, and
could potentially result in avoidable complications and
adverse events. The median time to onset of SSI suggests
that a prophylaxis regimen is a relevant factor, hence
practice changes remain indicated. Extremely late onset
of SSI occurs much less frequently and, for these patients,
surgical antibiotic prophylaxis practices may be less rele-
vant, although this should not preclude optimisation of
peri-operative practices.
Despite the lack of high-level evidence proving one
antibiotic superior to others, there have been efforts in
North America to establish a consensus. In Canada, a
2009 survey of antibiotic prophylaxis for total joint
arthroplasty (TJA) surgery showed that 97.3% of surgeons
surveyed routinely administered cefazolin as their first
line prophylaxis.42 In the United States, the American
Academy of Orthopaedic Surgeons recommend that
cefazolin or cefuroxime are the preferred intravenous
antibiotics to be used as prophylaxis in primary TJA.43
With rates of SSI reported as approximately 1% in the
United States and Canada, their results are comparable
with the United Kingdom and Europe. It is therefore diffi-
cult to understand why such variation exists in the United
Kingdom. One possibility is that antibiotic choice is influ-
enced by organisational aversion to certain antibiotics,
e.g., following high-profile CDI outbreaks. For example,
those that are averse to cephalosporins may be more
likely to use the dual combination flucloxacillin and gen-
tamicin. The 2014 English surveillance programme for
antimicrobial utilisation and resistance (ESPAUR) report
includes a national survey on antimicrobial stewardship
in secondary care in 2014. A total of 99 (67.8%) of 146
contacted acute NHS Trusts responded to the survey. Of
those, 98% of Trusts reported the use of surgical anti-
biotic prophylaxis policy. However, just over 80% of
Trusts implemented audits of compliance to antibiotic
guidelines (dose, route and duration). Although this is
high further improvement in the process, monitoring is
needed as this activity is key in order to influence changes
in practice. The report also found that 24% of survey
respondents had a written antimicrobial education and
training strategy.23 These results may, in part, explain the
variation in surgical prophylaxis that we observed in our
study. Another explanation that could account for some
of the variation in regimens is that it could reflect local
analyses of infecting organisms. There is, however, no
obvious reason why the United Kingdom should not aim
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to establish a consensus in the same way as has been
achieved in North America. 
It is arguable that the financial burden, morbidity, and
mortality associated with SSIs following THA and TKA are
sufficient to support efforts to undertake further research
in this field. This research should focus on establishing the
safest regimen/dose, by comparing complications such
as SSI, AKI, CDI rates, and rates of MRSA infection. We
would suggest that the National Joint Registry collect
data on antibiotic(s) used including dose, route, dura-
tion, and timings. This data could then be combined with
that already collected by PHE including rates of SSI, CDI
and MRSA.
Supplementary material
Further information and tables detailing antibiotic
prophylaxis regimes, including dose, duration and
most commonly used regimes, in routine, penicillin
allergy, and cases presenting a high risk of MRSA, as well
as a map demonstrating the ‘super regions’ can be found
alongside the online version of this article at
www.bjr.boneandjoint.org.uk
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